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Abstract
Objectives: The aim of the study was to determine the rate of Potentially Inappropriate Medicines (PIM) and Potential
Prescription Omissions (PPO) according to Screening Tool of Older Person’s potentially inappropriate Prescriptions/
Screening Tool to Alert doctors to the Right Treatment (STOPP/START) criteria.
Study Design: A cross-sectional survey in community pharmacy.
Method: A prospective cross-sectional study was performed, during March-May 2012, in five community pharmacies.
Patients aged $65 years, who collected one or more prescribed medications, were asked to participate in the study, and an
interview was scheduled. Patients were asked to provide their complete medical and biochemical record from their general
practitioner.
Results: 509 patients, mean age 74.866.5 years, 57.4% female, participated in the study. 164 PIM were identified in 139
patients (27.3%). The most common were: long-term use of long-acting benzodiazepines (20.7%), use of non-steroidal
antiinflammatory drugs (NSAID) in patients with moderate-severe hypertension (20.1%), use of theophylline as
monotherapy for chronic obstructive pulmonary disease (COPD, 15.9%) and use of aspirin without appropriate indication
(15.2%). Patients with more than four prescpritions had a higher risk for PIM (OR 2.85, 95% CI 1.97–4.14, p,0.001). There
were 439 PPO, identified in 257, (50.5%) patients. Predictors for PPO were older age, presence of diabetes, myocardial
infarction, osteoporosis, stroke, COPD and/or angina pectoris.
Conclusion: STOPP/START criteria may be useful in identifying inappropriate prescribing and improving the current
prescribing practices. Pharmacists should focus more on patients with more than four medications and/or patients with
gout or pain accompanied with arterial hypertension because those patient may be at higher risk of PIM. Additionlly,
patients older than 74 years with diabetes, osteoporosis, myocardial infarction, stroke, angina pectoris and/or COPD may
have an increased risk of PPO.
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Introduction
Older people have an increased risk of multimorbidity and are
more likely to be prescribed several medications concomitantly,
which increases the risk of adverse drug events (ADE) [1]. Studies
have shown that inappropriate prescribing is common in older
hospitalized patients [2,3] and that it may lead to increased risk of
hospitalization [4,5]. A medication is considered inappropriate if
the risk of ADE outweighs the clinical benefit, particularly if safer
and/or more effective medications are available for the condition.
Also, prescription of a medication at an excessive dose, prolonged
duration, prone to drug-drug or drug-disease interactions is
inappropriate [6]. Moreover, there is an increasing awareness,
among health care providers, that omission of potentially
beneficial medications from treatment is inappropriate as well [6].
Several tools are available for detecting inappropriate prescrib-
ing. The most commonly used worldwide are the Beers’ criteria
developped by a panel of experts [7]. However, Beers’ criteria
have several limitations since drug-drug interactions and poten-
tially inappropriate drug omissions are not considered which may
lead to underestimation of potentially inappropriate prescribing.
Another tool called STOPP (Screening Tool of Older Person’s
Prescriptions) and START (Screening Tool to Alert doctors to
Right Treatment) has been developed by an Irish group of authors
[8]. STOPP criteria consist of 65 indicators which detect
Potentially Inappropriate Medicines (PIM) including drug-drug
and drug-disease interactions. START criteria comprise 22
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indicators of Potential Prescribing Omissions (PPO) in older
people. Recent reviews endorse the use of STOPP/START over
Beers’ criteria in detecting inappropriate prescribing in the elderly
[9–11].
STOPP/START criteria have shown high prevalences of PIM
and PPO in hospitalized and nursing homes patients [2,3,12,13].
However, only few studies have adressed the use of these tools in
primary care [14,15]. Pharmacists, as most accesible members of
the health care team in primary care, may play an important role
in detecting potentially inappropriate prescribing in the older
population. Morever, the role of pharmacists was supported by the
good inter-rater reliability between pharmacists and physicians
when STOPP/START criteria were applied to the same patient
profiles [16,17].
The aim of the study was to determine the rate of PIM and PPO
according to STOPP/START criteria in community pharmacies.
Methods
Study setting and population
A prospective cross-sectional study was performed on a group of
older patients by five community pharmacists in three regions in
Serbia. All five pharmacies were located in urban areas. This study
was a part of a larger research project initiated by Academic staff,
with the intention to promote research among primary and
secondary care pharmacists. Within the project, five community
pharmacists were trained and assigned to investigate inappropriate
prescribing according to STOPP/START criteria.
All patients aged $65 years, who presented in the pharmacy in
order to collect one or more prescribed medications, were asked to
participate in the study. Patient interview was scheduled upon
mutual agreement, and patients were asked to provide their
complete medical and biochemical record from the past year. On
patient’s request, all data were issued by the general practitioner,
since pharmacists do not have access to electronic patient records.
Data collection
Data were collected during a 3-month period, between March
and May 2012. An Ethical Committee approval for the research
was obtained by the Faculty of Pharmacy, University of Belgrade.
Patients were informed about the aims of the study and had to give
a written consent.
A questionnaire for demographic, clinical and laboratory data
which included age, gender, current diagnoses and medical
problems, medical histories, current medications and relevant
biochemical data was used. In the event that research pharmacists
were uncertain about the diagnosis, interpretation of biochemical
data and application of screening tools, they reffered to a senior
academic pharmacist and two teacher-practitioner pharmacists at
the Faculty of Pharmacy.
Application of STOPP/START criteria to collected data was
performed by community pharmacists and reviewed by teacher-
practitioners.
Statistical analysis
All data were collected using Microsoft Excel 2003. Statistical
analysis was performed with PASW 18.0 (SPSS Inc., Chicago, IL,
USA). Continuous varibles in the text and tables were expressed
by mean 6 S.D. and categorical data were presented as
percentage. Multivariate logistic regression was used to determine
independent risk factors that were associated with PIM or PPO.
Disease/condition with more than one PIM or PPO, age
categorized into groups: 65–74, 75–84 and .85 years, number
of prescribed drugs categorized into groups: 1–4, 5–8 and .9 and
sex were entered in the logistic regression analysis and a model was
built using the stepwise method wich excluded variables at a
selection threshold of 0.1. The results of the regression analysis are
presented with odds ratios (OR) and their 95% confidence




Out of 547 patients who were asked to participate 509 patients
(93%) were included in the study. Their characteristics are shown
in Table 1. The mean age was 74.866.5 years, 57.4% were
female. 2621 medications were prescribed and 54 diagnoses were
recorded. 37% of patients had more than 5 medications
prescribed.
Potentially Inappropriate Prescribing
According to STOPP criteria 164 PIM were identified in 139
patients (Table 2). 17 out of 65 STOPP indicators identified
inappropriate prescribing in this study. The most common were:
long-term use of long-acting benzodiazepines (20.7%), use of non-
steroidal antiinflammatory drugs (NSAID) in patients with
moderate-severe hypertension (20.1%), use of theophylline as
monotherapy for chronic obstructive pulmonary disease (COPD,
15.9%), use of aspirin without appropriate indication (15.2%) and
duplication of therapy (10.4%) (Table 3).
72.8% of PIM were associated with four diagnoses: osteoar-
thritic pain, anxiety, COPD and primary prevention of cardio-
vascular events.
Using multivariate regression analysis, we identified indepen-
dent risk factors for PIM in our cohort (Table 4). Patients with
more than 4 medications were at higher risk for having PIM (5–8
medications OR 2.56, 95% CI 1.75–3.74, p,0.001 and $9
medications OR 7.43, 95% CI 3.20–17.23, p,0.001).
A statistically significant higher risk for PIM was identified for
pain accompanied by arterial hypertension (OR 31.27, 95% CI
15.01–65.17, p,0.001) and gout (OR 10.26, 95% CI 3.10–34.01,
p,0.001). Patients with osteoarthritic pain and arterial hyperten-
sion were often prescribed prolonged NSAID treatment (75.6%).
Gout was associated with the prescribing of thiazide diuretics
(54.5%).
Potential Prescription Omissions
START identified a total of 439 PPO in 257 (50.5%) patients
(Table 2). 15 of the 22 START criteria identified omissions in this
study. The cardiovascular and endocrine system accounted for
most PPO (88.6%). Lack of antiplatelet therapy and statins in
patients with history of coronary, cerebral or peripheral vascular
disease or in patients with diabetes mellitus with co-existing major
cardiovascular risk factors were the most common omissions.
Morover, b-blockers were omitted in the treatment of patients with
angina pectoris and patients with COPD were omitted regular
inhaled b2-agonists or anticholinergics. No omissions were
identified under the gastrointestinal system criteria.
Patients older than 74 years were more likely to have a PPO
(75–84 years OR 1.47, 95% CI 1.01–2.13, p = 0.041 and $85
years OR 1.79, 95% CI 1.19–2.83, p = 0.009).
Following diagnoses were identified as indipendent predictors of
prescribing omissions (Table 4): diabetes (OR 69.55, 95% CI
38.55–125.49, p,0.001), myocardial infarction (OR 14.82, 95%
CI 6.69–32.86, p,0.001), osteoporosis (OR 14.73, 95% CI 4.08–
53.11, p,0.001), stroke (OR 12.19, 95% CI 4.40–33.80, p,
0.001), COPD (OR 5.64, 95% CI 3.12–10.20, p,0.001) and/or
STOPP/START Criteria Use in Community Pharmacy
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angina pectoris (OR 3.85, 95% CI 2.49–5.96, p,0.001). Patients
with diabetes and increased cardiovascular risk lacked statins in
their treatment in 91.2% of cases. Osteoporosis was associated
with lack of supplementation with calcium and vitamin D (78.6%)
whereas angina pectoris was not treated with b-blockers (47.2%)
and COPD patients lacked regular inhaled b2 agonists or
anticholinergics (57.5%). Moreover, 75% of patients with myo-
cardial infarction or stroke were associated with at least one
omission regarding use of aspirin, statin or ACE inhibitor, where
indicated.
Discussion
The results of the study indicate a substantial rate of PIM and
PPO in a cohort of older primary care patients in Serbia. The
prevalence of PIM among primary care patients in our study was
comparable to other reports (14.8–36.0%) [15,18,19]. Higher
prevalence of PIM was reported in hospitalized patients, patients
on admission to hospital (35–79%) [2–4,20–22] and in nursing
homes (59.8–79%) [12,13].
We observed not only a difference in prevalence of PIM among
reports but also a different pattern of inappropriate prescribing in
primary and secondary care patients. Most frequent PIM in our
study were associated with five STOPP indicators: long-term use
of long-acting benzodiazepines, NSAID use in patients with
moderate to severe hypertension, theophylline monotherapy in
patients with COPD, aspirin in patients with no history of vascular
symptoms and occlusive events and duplication of therapy. The
results of Ryan et al. [15] were similar to some extent and reported
a high occurrence of proton pump inhibitor (PPI) use for more
than 8 weeks (29.4%), long-term use of long-acting benzodiaze-
pines (19.9%), NSAID use in patients with moderate to severe
hypertension (11.3%), duplication of therapy (8.4%) and the use of
a cardioselective b-blocker in COPD (6.4%), whereas Yayla et al.
[18] reported duplication of therapy (64.6%) and aspirin use
(18.8%) to be most frequent.
In contrast, reports from hospitalized patients revealed higher
prevalence of inappropriate prescribing in patients prone to falls
(14.2–15.2%) and use of calcium channel blockers in chronic
constipation (4.2–12.3%). The five most common STOPP
indicators accounted for only 20.3–38.7% of PIM [2,3]. Preva-
lence of PPI use for more than 8 weeks (8.2%), use of aspirin in
patients with no history of vascular symptoms and occlusive events
(4.9%) and use of long-term long-acting benzodiazepines (2.5–4%)
was lower compared to primary care [2,3].
The START tool, used together with STOPP criteria, enabled
a more complete assessment of potential inappropriate prescribing
in older people. PPO in our population were more frequent
compared to the Irish population (50.5% vs 22.7%) [15].
However, our results were comparable to those in hospitalized
patients (34–59.4%) [2,3,21,23] and nursing homes (42.2–74%)
[12,13]. Most prevalent were PPO in patients with cardiovascular
diseases, diabetes, osteoporosis and COPD, in all assessed studies
[2–4,13]. We found highest prevalence of PPO in patients with
diabetes followed by cardiovascular diseases which is in concor-
dance with the results in Taiwanese hospital patients [2]. Other
studies reported highest prevalence of PPO in cardiovascular
patients (31.5–55.6%) [3,15].
Table 1. Characteristics of the study population.
Population characteristics Total (n = 509)
Age, mean6S.D., range 74.866.5, (65–95)
Sex (female), n, (%) 292, (57.4)
Number of drugs prescribed 2621
Drug prescriptions per patient, mean6S.D., range 5.162.2, (1–16)
Number of diseases/conditions 54
Number of diseases/conditions per patient, mean6S.D., range 3.161.4, (1–8)
Most frequent diagnoses, n, (%)
Arterial hypertension 460, (90.3)
Diabetes mellitus 148, (29.1)
Cardiac failure 115, (22.6)
Anxiety 96, (18.9)
Angina pectoris 89, (17.5)
Prostate hyperplasia 72, (14.2)
Depression 53, (10.4)
doi:10.1371/journal.pone.0095536.t001
Table 2. Number of potentially inappropriate prescriptions
according to STOPP and START criteria.
Number of potentially inappropriate
prescriptions STOPP START
n, (%) n, (%)
1 118, (23.2) 118, (23.2)
2 18, (3.5) 104, (20.4)
3 2, (0.4) 29, (5.7)
4 1, (0.2) 4, (0.8)
5 0 2, (0.4)
Total 164, (27.3) 439, (50.5)
doi:10.1371/journal.pone.0095536.t002
STOPP/START Criteria Use in Community Pharmacy
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Number of medications prescribed for PIM and age for PPO
were identified as independent risk factors in our study. Similar
results were reported by Gallagher et al. [3] while other reports
identified number of medication and age as independent risk
factors for PIM but not for PPO [2,15].
Our results revealed the presence of a disease/condition as an
independent risk factor for PIM/PPO. Pain in patients with
moderate to severe hypertension and/or gout were predictors for
PIM, whereas the presence of diabetes mellitus, osteoporosis,
myocardial infarction, stroke, COPD and angina pectoris were
independent risk factors for PPO. There is some discrepancy
between most frequent STOPP indicators and the diseases which
predispose to PIM. This may be explained by different indications
for the use of long-acting benzodiazepines which were encoun-
tered among our patients, the inability to associate therapy
duplication with a specific disease and the high prevalence of
hypertension associated with primary prevention aspirin use. In
opposite, the diseases/conditions predisposing to PPO were in
accordance with most frequent START indicators.
Several studies have shown a beneficial impact of community
pharmacists in improving older patients’ health care outcomes
[24–27]. The use of STOPP/START criteria in improving health
care outcomes in primary care, remains to be established.
However, recent findings in secondary care may be promising
[28–30]. It has been argued that primary care pharmacists may
overestimate the rate of PIM and underestimate the rate of PPO
when using STOPP and START criteria due to lack of clinical
information [14]. In some cases, what is considered inappropriate
Table 3. Most frequently encountered potentially inappropriate prescriptions according to STOPP and START criteria.
STOPP and START criteria Total
STOPP
Digoxin .125 mg/day in renal impairment 4
Loop diuretics as first-line monotherapy for hypertension 2
Thiazide diuretics with a history of gout 6
b-blocker in combination with verapamil 1
Aspirin with history of peptic ulcer without gastro-protection 2
Aspirin with no history of vascular symptoms or occlusive event 25
Aspirin to treat dizziness without cerebrovascular disease 1
Long-term use of long-acting benzodiazepines 34
Long-term use of neuroleptics as long-term hypnotics 1
Long-term use of neuroleptics in those with Parkinsonism 1
Theophylline as monotherapy for COPD 26
NSAID with history of peptic ulcer without gastro-protection 1
NSAID with moderate-severe hypertension 33
Warfarin and NSAID together 3
Long-term corticosteroids as monotherapy for rehumathoid arthritis 1
Glibenclamide with Type 2 diabetes mellitus 6
Duplication of therapy 17
START
Warfarin in the presence of chronic atrial fibrilation 14
Aspirin or clopidogrel in patients with vascular disease and sinus rhythm 37
Statin therapy with history of vascular disease 15
ACE inhibitor with chronic heart failure 30
ACE inhibitor following acute myocardial infarction 7
b-blocker with chronic stable angina 43
Regular inhaled b2 agonist or anticholinergic agent in asthma or COPD 30
L-dopa in idiopathic Parkinsonism 4
Disease-modifying antirheumatic drug in rheumathoid disease 2
Bisphosphonates in patients taking maintenance corticosteroid therapy 2
Calcium and Vitamin D supplementation in osteoporosis 11
Metformin in Type 2 diabetes mellitus 17
ACE inhibitor in diabetes with nephropathy 2
Antiplatelet therapy in diabetes mellitus with cardiovascular risk 108
Statin therapy in diabetes mellitus with cardiovascular risk 117
ACE, angiotensin converting enzyme; COPD, chronic obstructive pulmonary disease; NSAID, non-steroidal antiinflammatory drug.
doi:10.1371/journal.pone.0095536.t003
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Table 4. Factors associated with potentially inappropriate prescribing according to STOPP/START criteria.
Factors STOPP
PIM No PIM p-value
Sex (female) 84 208 n.s
Number of medications
1–4 35 173
5–8 89 177 ,0.001
$9 15 10 ,0.001
Age
65–74 77 195
75–84 44 148 n.s.
$85 18 27 n.s.
Diagnosis
Pain/arterial hypertension 31 10 ,0.001
Gout 6 5 ,0.001
Anxiety 28 68 n.s
Arterial hypertension 41 419 n.s.
Asthma 2 14 n.s
Depression 9 44 n.s
Diabetes mellitus 6 142 n.s.
COPD 24 23 n.s.
Myocardial infarction 3 33 n.s.
Rheumathoid arthritis 4 11 n.s.
Cardiac failure 5 110 n.s.
Sleep disorder 3 9 n.s.
START
PPO No PPO p-value
Sex (female) 181 111 n.s.
Number of medications
1–4 103 105
5–8 135 131 n.s.
$9 19 16 n.s.
Age
65–74 124 148
75–84 106 86 0.041
$85 27 18 0.009
Diagnosis
Diabetes mellitus 135 13 ,0.001
Osteoporosis 11 3 ,0.001
Myocardial infarction 28 8 ,0.001
Stroke 15 5 ,0.001
COPD 27 20 ,0.001
Angina pectoris 47 42 ,0.001
Atrial fibrillation 12 15 n.s
Cardiac failure 29 86 n.s
Parkinsonism 4 7 n.s
Prosthetic heart valve 2 9 n.s
Arterial hypertension 2 458 n.s
Asthma 3 13 n.s
STOPP/START Criteria Use in Community Pharmacy
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according to STOPP/START may be appropriate for the
individual patient for many reasons and this is difficult to assess
without communication with the prescriber. Our pharmacists
reviewed patient’s medical and biochemical data based on the
general practitioner’s report. The similar results of PPO in our
study compared to hospitalized patients may indicate the
robustness of START criteria in primary and secondary care.
Nevertheless, we observed differences in PIM between primary
and secondary care patients. The reasons for the difference in the
number and prevalence of different PIM are probably multifac-
torial. Hospitalized patients are generally sicker and frailer than
primary care patients. Older age, more medicines prescribed,
more comorbidities and a higher severity of illness could have
accounted for the number and diversity of PIM.
There were some limitations to our study. Number of patients
for data collection as well as exclusion of patients who did not
claim prescriptions personally, limits the generalizability of
findings. Furthermore, clinical information for assessing inappro-
priate prescribing and omissions may have been incomplete since
their was no close communication with prescribers. Nevertheless,
this study showed that community pharmacists were able to
identify many cases of inappropriate prescribing using easily
applicable screening tools such as STOPP/START criteria.
Conclusion
27.3% of patients with PIM and 50.5% with PPO were
observed in our study indicating that STOPP/START criteria
may be useful in identifying inappropriate prescribing and
improving the current prescribing practices. Pharmacists should
focus more on patients with more than four medications and/or
patients with gout or pain accompanied with arterial hypertension
because those patient may be at higher risk of PIM. Additionlly,
patients older than 74 years with diabetes, osteoporosis, myocar-
dial infarction, stroke, angina pectoris and/or COPD may have an
increased risk of PPO.
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